Last reviewed · How we verify
NCT04269928
Effects of Adrenal Artery Ablation and Adrenalectomy in Patients With Primary Aldosteronism
trial testing Endovascular chemical ablation of adrenal gland in Primary Aldosteronism in 110 participants. Completed in 1 June 2021.
30 December 2019
Quick facts
| Lead sponsor | Third Military Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 19 January 2016 |
| Primary completion | 30 December 2019 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Endovascular chemical ablation of adrenal gland
Conditions studied
- Primary Aldosteronism — all drugs for Primary Aldosteronism →
- Hypertension — all drugs for Hypertension →
Sponsor
Third Military Medical University
Who can join
Adults 30 to 65, any sex, with Primary Aldosteronism or Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary aldosteronism (PA) is the main cause of secondary hypertension, affecting 5-15% of the general hypertensive population. Early diagnosis and treatment are of crucial importance as patients with PA are more susceptible to cardiovascular and cerebrovascular morbidity and mortality than blood-pressure-matched hypertensive patients. Current guidelines indicate that mineralocorticoid receptor (MR) antagonists and laparoscopic adrenalectomy are the principal treatments for PA.Laparoscopic adrenalectomy is recommended for patients with aldosteronoma or unilateral adrenal hyperplasia. During the past two decades, catheter-based arterial embolization or computed tomography (CT)-guided radiofrequency thermogenesis have been used for aldosteronomas treatment. Although these procedures are claimed to be effective for treatment of aldosteronomas, the evidence comes mostly from case reports or small series. In addition, some PA patients refuse surgery and are intolerant of the adverse effects of MR antagonists; others have persistence of PA after adrenelectomy, but respond poorly to MR antagonists. An alternative therapy is needed in such cases. In recent years, adrenal artery ablation has also been used to treat primary aldosteronism, which can reduce the level of aldosterone and blood pressure, but its efficacy and safety are not clear. To confirm the effect of adrenal artery ablation on blood pressure, RAAS system and blood potassium, the researchers conducted a parallel control clinical study of patients with primary aldosteronism (Aldosteronoma).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04269928
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Aldosteronism
Currently open trials in the same condition.
- NCT07298954 — Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE) · NA · recruiting
- NCT07111351 — Multi-omics Studies of Primary Aldosteronism · recruiting
- NCT07027254 — PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism · NA · recruiting
- NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
- NCT06955286 — Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Witho · recruiting
Other Third Military Medical University trials
Trials by the same sponsor.
- NCT07536477 — High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema · NA · not yet recruiting
- NCT07488507 — Diagnostic Value and Safety of Combined Biopsy for Mediastinal Metastasis of Lung Cancer · NA · recruiting
- NCT07277907 — Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation · Phase 3 · recruiting
- NCT04557995 — Erythrocytapheresis for Chronic Mountain Sickness · NA · recruiting
- NCT07036588 — PARLAR-02 Trial：Modified Transanal Drainage Tube Use for Preventing Anastomotic Leakage · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04269928 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Third Military Medical University
- Last refreshed: 22 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04269928.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing